Glucocorticoids (both bioidentical and synthetic) are some of the most widely used drugs in the clinical setting, as well as in outpatient treatment for all sorts of ailments – i.e. autoimmune conditions, joint pain, post-operative inflammation, asthma, and even infectious diseases such as COVID-19. The officially improved indications for those glucocorticoid drugs continue to increase despite mountains of evidence that such drugs do not improve the long-term outcomes of any disease, and are at best simply masking symptoms. A recent post of mine discussed a study directly claiming that glucocorticoid usage sets up the stage for pro-inflammatory environment, which would explain why patients deteriorate (compared to baseline) the moment they stops using said drugs. The mechanism mentioned by that study was a fairly obscure one, so it probably won’t satisfy most of my critics as good evidence for the pro-inflammatory risks of long-term usage of such drugs. Hopefully, the human study below will provide that stronger evidence, as it demonstrates that glucocorticoids increase the expression of the COX-2 enzyme in-vivo, which is in direct contradiction to official claims of mainstream medicine. Namely, one of the major reasons for using glucocorticoids in medicine is the claim (by doctors and public health agencies) that they suppress COX-2 expression. COX-2 is the main producer of prostaglandins from PUFA (omega-6 and omega-3), and the prostaglandins are responsible for 60%-80% of the inflammatory cascade. As such, COX-2 inhibitors like aspirin and other NSAID are widely prescribed as prevention/treatment of inflammatory conditions, and the same benefit is not only being ascribed to glucocorticoids, but the claim is that the latter are even more potent than NSAID at inhibiting COX-2. Well, apparently not, as per the study below. Even if those drugs inhibit COX-2 activity, increasing its expression sets up the stage for a much stronger inflammatory response (compared to baseline) the moment the glucocorticoids are discontinued, so the outcome is worse than the classical “borrow from Peter to pay Paul”. This would explain why long-term usage of glucocorticoids invariably worsens the chronic condition for which it is being prescribed, while also dramatically raising the risk for virtually any type of cancer (another condition caused/promoted by chronic inflammation). Once again, it seems that the truth in the (medical) world is often about 180 degrees away from the “expert opinion”.
“…At week 12, cyclooxygenase-2 expression remained high in nonasthmatics while it decreased in asthmatics. Cyclooxygenase-2 protein was not detected under any circumstances. Glucocorticoid therapy enhances cyclooxygenase-2 expression in vivo in nasal polyps, a finding that does not follow the generally accepted assumption that cyclooxygenase-2 expression is suppressed by glucocorticoids.”